Antiandrogens in prostate cancer endocrine therapy

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• Prostate cancer is a prevalent malignancy in industrialized nations.
• Current endocrine therapies, including luteinizing hormone-releasing hormone (LHRH) agonists and antiandrogens, are palliative and target androgen signaling.
• Therapy resistance often develops due to alterations in the androgen receptor (AR).

Purpose of the Study:

• To review the mechanisms of resistance in prostate cancer endocrine therapy.
• To highlight the role of the androgen receptor (AR) in therapy resistance.
• To suggest new therapeutic strategies targeting AR expression and function.

Main Methods:

• Review of existing literature on prostate cancer, endocrine therapy, and androgen receptor biology.
• Analysis of mechanisms underlying therapy resistance.
• Identification of potential targets for novel therapeutic interventions.

Main Results:

• Androgen receptor (AR) mutations and increased AR expression contribute to resistance against LHRH agonists and antiandrogens.
• AR can be activated by non-androgenic stimuli, including growth factors and cytokines.
• Alterations in AR-associated proteins (coactivators, corepressors) may play a role in prostate cancer progression.

Conclusions:

• Existing endocrine therapies for prostate cancer are limited by the development of resistance.
• Targeting AR expression and function, potentially through novel mechanisms or by modulating AR-interacting proteins, is crucial for overcoming resistance.
• Further research into AR biology and its associated proteins may lead to more effective prostate cancer treatments.